CA3025681A1 - Anti hla-g specific antibodies - Google Patents
Anti hla-g specific antibodies Download PDFInfo
- Publication number
- CA3025681A1 CA3025681A1 CA3025681A CA3025681A CA3025681A1 CA 3025681 A1 CA3025681 A1 CA 3025681A1 CA 3025681 A CA3025681 A CA 3025681A CA 3025681 A CA3025681 A CA 3025681A CA 3025681 A1 CA3025681 A1 CA 3025681A1
- Authority
- CA
- Canada
- Prior art keywords
- hla
- seq
- antibody
- antibodies
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305650.0 | 2016-06-03 | ||
| EP16305650 | 2016-06-03 | ||
| PCT/EP2017/063503 WO2017207775A1 (en) | 2016-06-03 | 2017-06-02 | Anti hla-g specific antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3025681A1 true CA3025681A1 (en) | 2017-12-07 |
Family
ID=56413601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3025681A Pending CA3025681A1 (en) | 2016-06-03 | 2017-06-02 | Anti hla-g specific antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20190233520A1 (enExample) |
| EP (1) | EP3464364A1 (enExample) |
| JP (2) | JP7034950B2 (enExample) |
| KR (1) | KR102465491B1 (enExample) |
| CN (2) | CN109563169B (enExample) |
| AU (1) | AU2017272875B2 (enExample) |
| BR (1) | BR112018074847A2 (enExample) |
| CA (1) | CA3025681A1 (enExample) |
| EA (1) | EA201892793A1 (enExample) |
| IL (1) | IL263266B2 (enExample) |
| MX (1) | MX2018014979A (enExample) |
| SG (2) | SG10202107205VA (enExample) |
| WO (1) | WO2017207775A1 (enExample) |
| ZA (1) | ZA201808332B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278590A (zh) * | 2021-04-23 | 2021-08-20 | 台州恩泽医疗中心(集团) | 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2730588A1 (en) | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| CA3025681A1 (en) | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| ES2916217T3 (es) | 2017-01-05 | 2022-06-29 | Kahr Medical Ltd | Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma |
| DK3565579T3 (da) | 2017-01-05 | 2023-09-04 | Kahr Medical Ltd | Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf |
| AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
| AR114789A1 (es) * | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
| MY201995A (en) | 2018-07-09 | 2024-03-28 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
| IL280102B1 (en) | 2018-07-11 | 2026-07-01 | Kahr Medical Ltd | Fusion protein containing PD1-4-1BBL and methods of using the same |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| WO2020023268A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
| BR112021003757A2 (pt) | 2018-08-31 | 2021-05-25 | Invectys SA | receptores de antígenos quiméricos contra múltiplas isoformas de hla-g |
| BR112021005868A2 (pt) * | 2018-09-27 | 2021-10-19 | Tizona Therapeutics | Anticorpos anti-hla-g, composições compreendendo anticorpos anti-hla-g e métodos de uso de anticorpos anti-hla-g |
| CN118909117A (zh) * | 2019-08-14 | 2024-11-08 | 安托拉诊疗公司 | 与lrp6蛋白结合的抗体及使用方法 |
| CN114846156A (zh) * | 2019-10-25 | 2022-08-02 | 英特莱克森有限责任公司 | Hla-h、hla-j、hla-l、hla-v和hla-y作为治疗和诊断靶 |
| CN115996952A (zh) * | 2020-06-11 | 2023-04-21 | 提圣纳医疗公司 | 对hla-g和另一种抗原具有结合特异性的双特异性免疫细胞接合子 |
| CN113045656B (zh) * | 2020-07-27 | 2022-03-08 | 台州恩泽医疗中心(集团) | 抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
| WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
| CN112794908A (zh) * | 2020-12-31 | 2021-05-14 | 杭州冰湖生物科技有限公司 | 一种抗hla-g抗体的制备及分析方法 |
| GB202111905D0 (en) * | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
| CN115925930B (zh) * | 2021-11-04 | 2025-10-31 | 台州恩泽医疗中心(集团) | 一种抗hla-g1、hla-g4及hla-g5异构体分子的单克隆抗体及其用途 |
| CN114605543B (zh) * | 2021-12-17 | 2023-11-07 | 台州恩泽医疗中心(集团) | 一种抗hla-g异构体分子hla-g5及hla-g6的单克隆抗体及其用途 |
| AU2023216270A1 (en) | 2022-02-04 | 2024-08-15 | Nkilt Therapeutics, Inc. | Chimeric ilt receptor compositions and methods |
| CN118946585A (zh) * | 2022-03-25 | 2024-11-12 | 怡诺安有限公司 | 抗hla-g嵌合抗原受体及其用途 |
| US20250297013A1 (en) * | 2022-03-25 | 2025-09-25 | Hk Inno.N Corporation | Hla-g-specific antibody and use thereof |
| CN115894687B (zh) * | 2022-03-31 | 2024-06-07 | 台州恩泽医疗中心(集团) | 一种抗hla-g1，-g2，-g5及hla-g6异构体分子的单克隆抗体及其用途 |
| CN115819583B (zh) * | 2022-03-31 | 2026-03-03 | 台州恩泽医疗中心(集团) | 一种抗hla-g分子的单克隆抗体及其用途 |
| CN116284387B (zh) * | 2022-07-15 | 2025-10-03 | 台州恩泽医疗中心(集团) | 一种抗hla-g2及hla-g6分子的单克隆抗体及用途 |
| CN117448412A (zh) * | 2022-07-26 | 2024-01-26 | 中山大学孙逸仙纪念医院 | CD158d分子、其中和抗体，及应用 |
| CN115975033A (zh) * | 2022-10-10 | 2023-04-18 | 中国科学院微生物研究所 | 一种lilrb1单克隆抗体及其应用 |
| WO2024108568A1 (zh) * | 2022-11-25 | 2024-05-30 | 深圳先进技术研究院 | 抗人类白细胞抗原-g纳米抗体及其制备方法与应用 |
| CN119080938B (zh) * | 2023-06-05 | 2025-06-24 | 东莞市朋志生物科技有限公司 | 抗25羟维生素d抗体、检测25羟维生素d的试剂和试剂盒 |
| EP4793288A1 (en) * | 2023-10-12 | 2026-08-19 | Imbiologics Corp. | Antibody specifically binding to hla-g, and use thereof |
| CN121005780A (zh) * | 2024-05-24 | 2025-11-25 | 合肥天港免疫药物有限公司 | 靶向hla-g的抗体或其抗原结合片段及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0819171A1 (en) * | 1995-04-07 | 1998-01-21 | The Regents Of The University Of California | Antibodies for the detection of hla-g |
| CN1312182C (zh) * | 2004-10-26 | 2007-04-25 | 四川新创生物科技有限公司 | 抗hla－g的单克隆抗体及分泌它的杂交瘤细胞株、癌症诊断试剂盒及其应用 |
| US8647871B2 (en) * | 2007-03-30 | 2014-02-11 | Escape Therapeutics, Inc. | Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells |
| EP2184070A1 (en) * | 2008-11-07 | 2010-05-12 | Hla-G Technologies | HLA-G proteins and pharmaceutical uses thereof |
| EP2264067A1 (en) * | 2009-06-18 | 2010-12-22 | Hla-G Technologies | HLA-G alpha 1 multimers and pharmaceutical uses thereof |
| CN101967191A (zh) * | 2009-07-28 | 2011-02-09 | 广州天美生物技术有限公司 | Hla-g抗体制备方法及其在医学中的应用 |
| CN102086459A (zh) * | 2009-12-08 | 2011-06-08 | 华中科技大学 | 一种融合蛋白免疫抑制剂及其制备方法和应用 |
| US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
| EP2730588A1 (en) * | 2012-11-12 | 2014-05-14 | Intelectys | Antibodies and fragments thereof raised against the alpha-3 domain of HLA-G protein, methods and means for their preparation, and uses thereof |
| US20190119385A1 (en) | 2015-03-27 | 2019-04-25 | University Of Southern California | Hla-g as a novel target for car t-cell immunotherapy |
| CA3025681A1 (en) | 2016-06-03 | 2017-12-07 | Invectys | Anti hla-g specific antibodies |
| TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
-
2017
- 2017-06-02 CA CA3025681A patent/CA3025681A1/en active Pending
- 2017-06-02 BR BR112018074847-1A patent/BR112018074847A2/pt unknown
- 2017-06-02 MX MX2018014979A patent/MX2018014979A/es unknown
- 2017-06-02 JP JP2018563104A patent/JP7034950B2/ja active Active
- 2017-06-02 US US16/306,267 patent/US20190233520A1/en not_active Abandoned
- 2017-06-02 IL IL263266A patent/IL263266B2/en unknown
- 2017-06-02 EA EA201892793A patent/EA201892793A1/ru unknown
- 2017-06-02 KR KR1020187037215A patent/KR102465491B1/ko active Active
- 2017-06-02 EP EP17728815.6A patent/EP3464364A1/en not_active Withdrawn
- 2017-06-02 WO PCT/EP2017/063503 patent/WO2017207775A1/en not_active Ceased
- 2017-06-02 AU AU2017272875A patent/AU2017272875B2/en active Active
- 2017-06-02 SG SG10202107205VA patent/SG10202107205VA/en unknown
- 2017-06-02 CN CN201780048691.4A patent/CN109563169B/zh active Active
- 2017-06-02 SG SG11201810149VA patent/SG11201810149VA/en unknown
- 2017-06-02 CN CN202210678074.5A patent/CN115286695A/zh active Pending
-
2018
- 2018-12-10 ZA ZA2018/08332A patent/ZA201808332B/en unknown
-
2020
- 2020-10-26 US US17/080,017 patent/US11111302B2/en active Active
-
2021
- 2021-03-25 US US17/212,165 patent/US20210309748A1/en not_active Abandoned
- 2021-09-03 US US17/466,607 patent/US11312774B2/en active Active
-
2022
- 2022-03-02 JP JP2022031638A patent/JP2022084670A/ja active Pending
- 2022-04-25 US US17/728,483 patent/US11634494B2/en active Active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113278590A (zh) * | 2021-04-23 | 2021-08-20 | 台州恩泽医疗中心(集团) | 表达α1α2结构域缺失的HLA-G异构体标准蛋白的细胞株及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| NZ788807A (en) | 2025-11-28 |
| US20210309748A1 (en) | 2021-10-07 |
| EA201892793A1 (ru) | 2019-06-28 |
| JP7034950B2 (ja) | 2022-03-14 |
| AU2017272875A1 (en) | 2018-12-20 |
| IL263266A (en) | 2018-12-31 |
| US11634494B2 (en) | 2023-04-25 |
| US11312774B2 (en) | 2022-04-26 |
| US20220251216A1 (en) | 2022-08-11 |
| WO2017207775A1 (en) | 2017-12-07 |
| AU2017272875B2 (en) | 2023-10-19 |
| KR102465491B1 (ko) | 2022-11-11 |
| IL263266B2 (en) | 2024-07-01 |
| US20210054081A1 (en) | 2021-02-25 |
| NZ748929A (en) | 2025-11-28 |
| SG11201810149VA (en) | 2018-12-28 |
| EP3464364A1 (en) | 2019-04-10 |
| CN109563169A (zh) | 2019-04-02 |
| CN109563169B (zh) | 2022-07-01 |
| BR112018074847A2 (pt) | 2019-03-26 |
| JP2022084670A (ja) | 2022-06-07 |
| SG10202107205VA (en) | 2021-08-30 |
| IL263266B1 (en) | 2024-03-01 |
| KR20190044589A (ko) | 2019-04-30 |
| CN115286695A (zh) | 2022-11-04 |
| US11111302B2 (en) | 2021-09-07 |
| JP2019528038A (ja) | 2019-10-10 |
| US20220056140A1 (en) | 2022-02-24 |
| ZA201808332B (en) | 2019-08-28 |
| US20190233520A1 (en) | 2019-08-01 |
| MX2018014979A (es) | 2019-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11634494B2 (en) | Anti HLA-G specific antibodies | |
| JP7215759B2 (ja) | ４－１ｂｂ抗体およびその製造方法と使用 | |
| JP7173993B2 (ja) | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 | |
| US20160152723A1 (en) | Antibodies and chimeric antigen receptors specific for cd19 | |
| AU2016206457A1 (en) | Antibodies and chimeric antigen receptors specific for ROR1 | |
| RS54259B1 (sr) | Humana anti-alfa-sinukleinska autoantitela | |
| EP3155014A1 (en) | Antibodies directed against cd127 | |
| EP3442567A1 (en) | Anti-psma antibodies and use thereof | |
| CA3126707A1 (en) | Multispecific binding proteins | |
| CN119278213A (zh) | 针对ctla-4的抗体及其使用方法 | |
| CN113727731B (zh) | 靶向pd-1和lag-3的双特异性抗体 | |
| EA043548B1 (ru) | Анти-hla-g специфические антитела |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220531 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240809 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241209 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250205 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250507 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250507 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250605 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250605 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D141 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CONDITIONAL ALLOWANCE Effective date: 20260216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260216 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260409 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260409 |